Two decimal places are retained because the source reports carry them and truncating would discard information where a laboratory genuinely reports it. The uncertainty budget on /methods/uncertainty-budget/ is the right thing to read alongside any purity figure on this site.
AX-2024-005039
Ipamorelin · 2 mg declared · Zhuhai Kerui Biotechnology Co., Ltd. · lot KP-2409-N5905
- Report ID
- AX-2024-005039
- Compound
- Ipamorelin
- Compound class
- Growth-hormone axis peptides
- Supplier
- KP — Zhuhai Kerui Biotechnology Co., Ltd.
- Batch / lot
- KP-2409-N5905
- Declared label claim
- 2mg
- Laboratory
- Kestrel Bioanalytical
- Assay date
- 01 Nov 2024
- Submitted
- 04 Nov 2024
- Quarter
- 2024-Q4
- Submitter
- a.wojcik
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 15 min gradient, 214 nm | 99.57 | % area | ≥ 99.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.43 | % area | ≤ 1.0 | PASS |
| Largest single impurity | RP-HPLC — C-terminal free acid (+1 Da) | 0.16 | % area | ≤ 1.00 | PASS |
| Identity | not ordered on this submission | not determined | — | required for VERIFIED status | NOT TESTED |
| Total peptide content | by difference from the gravimetric mass balance | 88.36 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 87.98 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 2.31 | mg | 2 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 2.032 | mg | 2 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 101.6 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 3.60 | % | ≤ 9.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 7.19 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.85 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Faint haze, clearing on standing | — | clear, no visible particulates | FAIL |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 5.72 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 15 min gradient | 4.36 | min | 4.45 ± 0.25 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 0.87 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 58,514 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [D-Trp]-epimer | 0.81 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Ipamorelin — main peak | 4.36 | 4,839,411 | 99.57 | — |
| 2 | C-terminal free acid (+1 Da) | 4.45 | 7,776 | 0.16 | +0.984 |
| 3 | des-Lys (−128 Da) | 4.25 | 7,776 | 0.16 | -128.095 |
| 4 | Aib-deletion sequence (−85 Da) | 4.22 | 2,916 | 0.06 | -85.053 |
| 5 | [D-Trp]-epimer | 4.30 | 2,430 | 0.05 | 0.000 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 3.60 |
| Counter-ion (acetate) | ion chromatography | 7.19 |
| Residual solvent + inorganic residue | estimated | 0.85 |
| Total peptide content | by difference | 88.36 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.39 | 99.57 | divergence +0.11 pp vs batch median |
| Total impurities (% area) | 0.61 | 0.43 | |
| Largest single impurity (% area) | not stated | 0.16 | |
| Water (%) | not stated | 3.60 | |
| Counter-ion (%) | 8.2 | 7.19 | |
| Peptide content (%w/w) | 87.7 | 88.36 | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Domestic warehouse despatch → submitter (2–8 °C, 12 d) → laboratory (courier, cold pack, 8 d) → assay.
- Assay date
- 01 Nov 2024
- Submitted to the index
- 04 Nov 2024
- Laboratory
- Kestrel Bioanalytical, Melbourne, Australia
- Method basis
- 15 min gradient · unit-resolution MS
- Verification status
- PURITY ONLY
Annotations 2
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot KP-2409-N5905 n=5
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2024-005037 | KP-2409-N5905 | Janoshik | 2024-Q4 | 99.16 | 3.89 | 97.7 | Buyer-sourced | 0 | PASS |
| AX-2024-005038 | KP-2409-N5905 | Janoshik | 2024-Q4 | 99.13 | 4.36 | — | Laboratory-retained | 0 | PASS |
| AX-2024-005040 | KP-2409-N5905 | Nordanalyt | 2024-Q4 | 99.28 | 3.65 | 103.6 | Buyer-sourced | 0 | PASS |
| AX-2024-005041 | KP-2409-N5905 | Medutest | 2024-Q4 | 99.28 | 4.04 | — | Buyer-sourced | 0 | PASS |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041377 | QYB | QYB-2605-H3558 | Nordanalyt | 2026-Q3 | 99.93 | 4.35 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041913 | SinoPep | SNP-2606-L4478 | PeptideMeter | 2026-Q3 | 98.88 | 5.28 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-041914 | SinoPep | SNP-2606-L4478 | Janoshik | 2026-Q3 | 99.14 | 5.49 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041909 | SinoPep | SNP-2606-L4478 | PeptideMeter | 2026-Q3 | 99.00 | 5.48 | 89.5 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041895 | SinoPep | SNP-2602-B3833 | Janoshik | 2026-Q3 | 99.93 | 4.72 | 105.9 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041898 | SinoPep | SNP-2602-B3833 | Nordanalyt | 2026-Q3 | 99.93 | 4.54 | 96.0 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041899 | SinoPep | SNP-2602-B3833 | PeptideMeter | 2026-Q3 | 99.93 | 4.96 | 90.1 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041891 | SinoPep | SNP-2602-B3833 | Janoshik | 2026-Q3 | 99.93 | 5.11 | — | Buyer-sourced | 1 | MARGINAL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043095 | Retatrutide | KP-2607-H5774 | Janoshik | 2026-Q3 | 95.81 | 5.48 | 105.2 | Buyer-sourced | 0 | FAIL |
| AX-2026-043094 | Retatrutide | KP-2607-H5774 | PeptideMeter | 2026-Q3 | 96.32 | 6.40 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-043096 | Retatrutide | KP-2607-H5774 | VendorInvestigate | 2026-Q3 | 96.48 | 6.05 | 104.9 | Buyer-sourced | 0 | FAIL |
| AX-2026-043090 | Retatrutide | KP-2607-H5774 | Janoshik | 2026-Q3 | 96.46 | 5.81 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-043091 | Retatrutide | KP-2607-H5774 | Janoshik | 2026-Q3 | 96.13 | 5.94 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-043077 | TB-500 | KP-2605-C5214 | Janoshik | 2026-Q2 | 99.61 | 5.64 | 90.2 | Buyer-sourced | 0 | PASS |
| AX-2026-043093 | Retatrutide | KP-2607-H5774 | Janoshik | 2026-Q3 | 96.54 | 5.54 | — | Buyer-sourced | 0 | PASS |
| AX-2026-043092 | Retatrutide | KP-2607-H5774 | Medutest | 2026-Q3 | 96.64 | 6.12 | — | Buyer-sourced | 1 | FAIL |